Soleno Therapeutics (SLNO) Operating Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Operating Expenses data on file, last reported at $63.3 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $63.3 million, up 38.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $198.6 million (down 5.41% YoY), and the FY2025 annual result was $181.0 million, down 3.56% from the prior year.
• Operating Expenses rose to $63.3 million in Q1 2026 per SLNO's latest filing, from $52.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $80.2 million in Q3 2024 and troughed at $5.6 million in Q4 2022.
• A 5-year average of $29.3 million and a median of $23.5 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 672.61% in 2024, then tumbled 45.25% in 2025.
• A 5-year view of Operating Expenses shows it stood at $5.6 million in 2022, then surged by 147.95% to $13.9 million in 2023, then soared by 324.99% to $59.1 million in 2024, then dropped by 11.78% to $52.2 million in 2025, then increased by 21.42% to $63.3 million in 2026.
• Business Quant data shows SLNO's Operating Expenses at $63.3 million in Q1 2026, $52.2 million in Q4 2025, and $43.9 million in Q3 2025.